Intranasal Carriers for Brain-Directed Peptides
Across polymer and gold-nanorod systems, the shared engineering challenge is not simply getting peptide-associated material into the brain, but protecting the peptide and showing that it remains functional after transport.
Evidence
Peptides can bind biological targets selectively, but delivery to the brain adds several barriers: enzymatic degradation, rapid clearance, and limited passage from the circulation into brain tissue. Two independent preclinical studies approached that problem through the nasal cavity, using nanocarriers with different materials and different peptide cargoes. Neither study tested clinical benefit. Together, they provide evidence about delivery feasibility and the separate question of whether a transported peptide remains active.
The newer study, first published July 8, evaluated a 15-amino-acid peptide designed to bind toxic amyloid-beta oligomers and block their aggregation. Researchers made nanoparticles from polylactic acid and poloxamer P188, then adsorbed the peptide onto their surface. According to the PubMed abstract, the resulting formulation had physicochemical characteristics considered suitable for nose-to-brain delivery.
The formulation was tested across several evidence layers. Laboratory assays indicated that the carrier preserved the peptide's anti-aggregation activity and protected it from enzymatic degradation. Cellular experiments found the nanoparticle-peptide combination biocompatible in the tested system and potentially internalized by neuronal cells. The abstract also reports that intranasally administered nanoparticles reached the brain in vivo. However, the ingested abstract does not identify the animal species, group sizes, administered amount, brain concentrations, regional distribution, effect sizes, or statistical uncertainty. It therefore supports a directional delivery finding, not a quantitative comparison with other carriers or evidence that amyloid pathology improved.
The second study attached acyl-ghrelin, a 28-amino-acid peptide hormone, to gold nanorods. The researchers first linked the peptide's C-terminus to a polyethylene glycol spacer, then joined that spacer to the nanorod through a gold-sulfur bond. They optimized an equal molar ratio of ghrelin and PEG to favor a single PEG substitution, because modification at multiple sites could reduce peptide activity or cross-link the nanorods. The final preparation carried an estimated 386 plus or minus 192 ghrelin molecules per nanorod.
Cell testing exposed a mouse substantia-nigra-derived line to the constructs for 24 hours. All nanorod formulations showed dose-dependent toxicity, while PEG-coated nanorods, with or without ghrelin, were more biocompatible than the unmodified nanorods. That result makes surface chemistry part of the safety question rather than a neutral delivery detail.
For the animal experiments, C57BL/6 mice received intranasal ghrelin-PEG-gold nanorods. A dose experiment used 10 or 20 micrograms of ghrelin equivalent and measured brains at 10 minutes; a time-course experiment used 10 micrograms and measured at 10, 30, and 60 minutes. Each animal group contained three mice. Brain ghrelin peaked at approximately 2,067.6 plus or minus 760.6 picograms per gram at 10 minutes, then declined to 1,031.5 at 30 minutes and 660.0 at 60 minutes. Active-ghrelin measurements did not significantly differ from total-ghrelin measurements, indicating that much of the detected peptide retained the acylated form recognized by the assay.
The researchers also measured phosphorylation of AMPK, a signaling readout associated in their prior work with ghrelin activity. The ratio of phosphorylated to total AMPK increased at 30 and 60 minutes after ghrelin-nanorod administration, while PEG-coated nanorods without ghrelin resembled the control. This supports retained pharmacological activity after delivery, but AMPK phosphorylation is a molecular marker, not evidence of improved cognition, neuronal survival, or disease course.
Analysis — Preserving Function Through Delivery
The cross-study convergence is a two-part delivery standard: a carrier must increase access to the brain while preserving the cargo's relevant function. The polymer formulation paired reported brain arrival with retained anti-amyloid aggregation activity and protection from enzymes. The gold-nanorod formulation paired a measured, short-lived rise in brain ghrelin with preservation of the active peptide form and a downstream signaling response. This is an analysis across studies, not proof that the two carriers use the same transport route or would work equally well.
A cautious hypothesis is that functional validation should be designed into peptide-carrier development rather than treated as a follow-up to biodistribution. Detecting a nanoparticle or peptide-associated signal in brain tissue can show exposure, but it cannot establish that the cargo remains structurally intact, reaches the intended cells, or changes disease biology. The studies address different pieces of that chain, yet neither completes it. A stronger comparison would measure intact peptide, carrier, regional brain localization, target engagement, and disease-relevant outcomes on the same time course. That design could distinguish true delivery of active cargo from transient whole-brain exposure.
Limitations
Both studies are preclinical feasibility experiments, and neither demonstrates safety or effectiveness in people. The amyloid-blocking peptide source was available to this workflow only as an abstract. Its missing species, sample-size, dose, concentration, regional-distribution, and statistical details sharply limit the specificity of conclusions. The abstract reports brain arrival but not whether the peptide altered amyloid burden, neuronal function, behavior, or disease progression.
The acyl-ghrelin study provides full methods and results, but its animal groups contained only three mice and observation ended at 60 minutes. The brain measurements were short-term and do not establish regional delivery to therapeutic targets. AMPK phosphorylation is consistent with ghrelin activity but is not a clinical or disease-modifying endpoint. The study also found dose-dependent cellular toxicity for every nanorod construct, despite improved biocompatibility after PEG coating, and it did not resolve chronic dosing, accumulation, immunogenicity, or off-target effects.
Because the studies used different peptides, carrier materials, assays, and endpoints, their numbers cannot establish that one platform is superior. Independent replication, direct tracking of intact peptide and carrier, longer pharmacokinetic and toxicology studies, and efficacy testing in relevant disease models would be required before translation could be judged.